Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 7, 2008

Takeda Licenses Recombineering Technology from Gene Bridges

  • Takeda Pharmaceutical obtained the rights to Gene Bridges’ Red/ET recombination technology.

    Red/ET is a method for DNA engineering that allows cloning, subcloning, and modification of DNA at any chosen position. Recombineering DNA using Red/ET has a number of advantages over conventional methods, such as independent of restriction sites, no size limits, no unwanted mutations, and quickness, according to Gene Bridges.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.